Methylated markers in Fragile X

January 6, 2011, AAAS

A "fingerprint" on a key gene in certain groups of people with Fragile X syndrome may be a litmus test for which patients can benefit from a new drug, reports a recent study of 30 patients with the syndrome. Fragile X is the most common cause of inherited intellectual retardation, affecting one in every 5,000 children worldwide.

Without a cure, Fragile X is caused by a mutation in a single gene, Fragile X Mental Retardation-1 or FMR1, where part of the gene is made longer than normal by additional repeats of DNA sequence. The degree of gene elongation varies from person to person; some individuals have little expansion and do not display symptoms of Fragile X whereas others have much more expansion, known as “full mutation.”

For individuals with full mutation the FMR1 gene is shut down, resulting in severe Fragile X symptoms, and abnormal development of neuronal connections in the brain important for learning and memory. Normally, the FMR protein keeps a protein called mGluR5 in check. mGluR5 belongs to a family of proteins called mGlu5 receptors that is essential for many aspects of normal brain function; yet in patients with Fragile X, the FMR protein is absent, causing over-activation of mGluR5 in the brain, leading to symptoms of the disease.

Here, Sébastien Jacquemont and colleagues treated a group of 30 patients with with a new drug that reduces the activity of mGluR5 in the brain. Not all patients showed improvement, but an analysis of those that did revealed that the promoter of the FMR1 gene (the control switch that that interacts with DNA to turn on gene activity) in those patients was fully tagged with methyl groups.

The methyl group tags signaled that the FMR1 gene was completely shut off in these patients, providing a possible signature of people with Fragile X who could benefit from mGluR5-blocking drugs. The team also ran a large set of tests designed to detect changes in behaviors, like hyperactivity and inappropriate speech in the patients.

While the new drug had no effect on behavior as measured by the first slew of tests, it did show an effect on a secondary group of tests, when compared to a group of patients given a placebo treatment. Taking a closer look, the authors found that each member of the group of patients with fully methylated FMR1 promoters showed improvement in behavior.

The group with partially methylated promoters showed no such changes. This correlation between response to treatment and methylation status of the FMR1 promoter sets the stage for future studies designed to test whether methylation can serve as a predictor of positive drug response in patients with Fragile X syndrome.

More information: "1 Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056," by S. Jacquemont et al., Science Translational Medicine, 6-Jan-2011.

Related Stories

Recommended for you

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

Highly mutated protein in skin cancer plays central role in skin cell renewal

February 20, 2018
Approximately once a month, our skin completely renews itself. If this highly coordinated process goes awry, it can lead to a variety of skin diseases, ranging from skin cancer to psoriasis. Cells lining such organs as skin ...

Study of smoking and genetics illuminates complexities of blood pressure

February 15, 2018
Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of ...

New mutation linked to ovarian cancer can be passed down through dad

February 15, 2018
A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.